Framingham Heart Study-Cohort (FHS-Cohort)
Note that you will be prompted to log in or register an account
Open BioLINCC Study See bottom of this webpage for request information
Dataset(s) Last Updated
April 11, 2023
Clinical Trial URLs
Primary Publication URLs
The Framingham Heart Study Group requires that the requestor must obtain full or expedited IRB/Ethics Committee review and approval to obtain these data. Waivers or a determination that the research is exempt from ethical regulations do not suffice.
Commercial Use Data Restrictions Yes
Data Restrictions Based On Area Of Research No
Specific Consent Restrictions
Consent for use of data by commercial investigators is tiered.
The data now include examination data from the first 32 clinical exams, selected ancillary data, and event follow-up through 2018.
The objectives of the Framingham Study are to study the incidence and prevalence of cardiovascular disease (CVD) and its risk factors, trends in CVD incidence and its risk factors over time, and familial patterns of CVD and risk factors. Other important objectives include the estimation of incidence rates of disease and description of the natural history of cardiovascular disease, including the sequence of clinical signs and systems that precede the clinically recognizable syndrome and the consequences and course of clinically manifest disease.
The Framingham Study began in 1948 under the U.S. Public Health Service and was transferred under the direct operations of the new National Heart Institute, NIH, in 1949. Participants were sampled from Framingham, Massachusetts, including both men and women. This was the first prospective study of cardiovascular disease and identified the concept of risk factors and their joint effects. The study has continued to examine participants every two years and is currently supported by a contract to Boston University from the NHLBI, and from many grants for specialized studies.
At entry to the study in 1948-1952, the study recruited 5,209 men and women, ages 28-62 years, living in Framingham, MA. As of February 28, 1999, there are 993 surviving participants.
The Framingham Study is a longitudinal investigation of constitutional and environmental factors influencing the development of CVD in men and women. Examination of participants has taken place every two years and the cohort has been followed for morbidity and mortality over that time period.
The cardiovascular disease conditions under investigation include coronary heart disease (angina pectoris, myocardial infarction, coronary insufficiency and sudden and non-sudden death), stroke, hypertension, peripheral arterial disease and congestive heart failure.
Please note that researchers must be registered on this site to submit a request, and you will be prompted to log in. If you are not registered on this site, you can do so via the Request button. Registration is quick, easy and free.
Resources AvailableStudy Datasets Only
- Data Dictionary (PDF - 37.0 MB)
- 30-Year Followup (Section 34) (PDF - 761.7 KB)
- An Epidemiological Investigation of Cardiovascular Disease (Section 36) (PDF - 322.0 KB)
- An Epidemiological Investigation of Cardiovascular Disease (Sections 1-2) (PDF - 1.6 MB)
- Epidemiological Background and Design (PDF - 60.2 KB)
- Framingham Eye Study II (FES II) Manual of Procedures (January 1988) (PDF - 1.3 MB)
- Data Coding Manuals
- Eye Exam Documentation
Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message. If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.